Regenxbio (RGNX) Non Operating Income (2015 - 2025)

Regenxbio's Non Operating Income history runs 11 years deep, the most recent figure standing at -$9.5 million for Q4 2025.

• On a quarterly basis, Non Operating Income fell 5326.92% year-over-year to -$9.5 million in Q4 2025; TTM through Dec 2025 was -$32.7 million, a 623.38% decrease from a year earlier, with the FY2025 full-year figure at -$32.7 million, down 623.38% from the prior year.
• Non Operating Income was little changed at -$9.5 million in Q4 2025 per RGNX's latest filing, from -$9.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.1 million in Q3 2023 and bottomed at -$9.5 million in Q3 2025.
• The 5-year median for Non Operating Income is -$3.3 million (2022), against an average of -$2.9 million.
• Across the five-year window, Non Operating Income surged 202.7% in 2024 and slumped 5326.92% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$6.2 million in 2021, then surged by 64.23% to -$2.2 million in 2022, then jumped by 139.06% to $862000.0 in 2023, then plunged by 78.89% to $182000.0 in 2024, then slumped by 5326.92% to -$9.5 million in 2025.
• Per Business Quant, the three latest RGNX Non Operating Income figures stand at -$9.5 million (Q4 2025), -$9.5 million (Q3 2025), and -$7.6 million (Q2 2025).